Invesco Ltd. Purchases 24,303 Shares of Xencor, Inc. (NASDAQ:XNCR)

Invesco Ltd., a global investment management firm, has announced that it has purchased 24,303 shares of Xencor, Inc. NASDAQXNCR in the third quarter. This represents an increase of approximately 4.6% in the company's stake in Xencor's stock. After the acquisition, Invesco Ltd. now owns a total of 555,809 shares of Xencor's stock.

Xencor, Inc. is a biopharmaceutical company that specializes in developing and commercializing novel therapies for the treatment of autoimmune diseases. The company has a portfolio of clinical-stage programs targeting various autoimmune disorders, including rheumatoid arthritis, psoriasis, and multiple sclerosis.

Invesco Ltd. is a leading global investment management firm that provides a wide range of investment products and services to individual and institutional clients. The company operates in more than 40 countries and has assets under management of over $1.2 trillion.

The acquisition of additional shares in Xencor, Inc. by Invesco Ltd. is likely seen as a vote of confidence in the company's potential for growth and success. It may also indicate that Invesco Ltd. believes that Xencor's stock is undervalued and has the potential for appreciation in the future.